Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
What Is New in Psychiatry and Psychopharmacology—2nd Edition
share announcement

What Is New in Psychiatry and Psychopharmacology—2nd Edition

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 5044

Special Issue Editor

Prof. Dr. Donatella Marazziti

E-Mail Website1 Website2
Guest Editor
1. Department of Clinical and Experimental Medicine, Section of Psychiatry, University of Pisa, Via Roma 67, 56100 Pisa, Italy
2. Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy
Interests: biological psychiatry; neurobiology; psychopharmacology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The first volume of this Special Issue was a great success (https://www.mdpi.com/journal/life/special_issues/QIBPZ6UU36); therefore, we invite you to publish your research in the second volume of this Special Issue.

Psychiatry and psychopharmacology are rapidly evolving on the basis of clinical observations, therapeutic demands, biomarkers, development of novel drugs beyond classical paradigms and, last but not least, challenges from a changing world, creating novel problems in this field.

It is evident that there is a major need for more targeted and effective drugs and more focused psychological interventions able to resolve the high percentage of non-response amongst patients with different disorders. Unfortunately, the demand for innovation may clash with current economic constraints, leading to more limited resources for clinical practice and research, as well as the shift toward the management of the COVID-19 pandemic.

For these reasons, the aim of this Special Issue is to put together a collection of papers dealing with some “hot topics” in the domains of psychiatry and psychopharmacology. Indeed, this Special Issue will include contributions on bipolar disorders, obsessive compulsive disorders, post-traumatic stress disorder, depression, agitation in children, biomarkers in addiction, therapeutic strategies for resistant cases, and new applications and targets of transcranial magnetic resonance.

Prof. Dr. Donatella Marazziti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical psychiatry
  • biomarkers
  • psychopharmacology
  • addictions
  • agitations
  • pharmacological resistance
  • transcranial magnetic resonance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1423 KiB  
Article
Application of the Random Forest Algorithm for Accurate Bipolar Disorder Classification
by Miguel Suárez, Ana M. Torres, Pilar Blasco-Segura and Jorge Mateo
Life 2025, 15(3), 394; https://doi.org/10.3390/life15030394 - 3 Mar 2025
Viewed by 742
Abstract
Bipolar disorder (BD) is a complex psychiatric condition characterized by alternating episodes of mania and depression, posing significant challenges for accurate and timely diagnosis. This study explores the use of the Random Forest (RF) algorithm as a machine learning approach to classify patients [...] Read more.
Bipolar disorder (BD) is a complex psychiatric condition characterized by alternating episodes of mania and depression, posing significant challenges for accurate and timely diagnosis. This study explores the use of the Random Forest (RF) algorithm as a machine learning approach to classify patients with BD and healthy controls based on electroencephalogram (EEG) data. A total of 330 participants, including euthymic BD patients and healthy controls, were analyzed. EEG recordings were processed to extract key features, including power in frequency bands and complexity metrics such as the Hurst Exponent, which measures the persistence or randomness of a time series, and the Higuchi’s Fractal Dimension, which is used to quantify the irregularity of brain signals. The RF model demonstrated robust performance, achieving an average accuracy of 93.41%, with recall and specificity exceeding 93%. These results highlight the algorithm’s capacity to handle complex, noisy datasets while identifying key features relevant for classification. Importantly, the model provided interpretable insights into the physiological markers associated with BD, reinforcing the clinical value of EEG as a diagnostic tool. The findings suggest that RF is a reliable and accessible method for supporting the diagnosis of BD, complementing traditional clinical practices. Its ability to reduce diagnostic delays, improve classification accuracy, and optimize resource allocation make it a promising tool for integrating artificial intelligence into psychiatric care. This study represents a significant step toward precision psychiatry, leveraging technology to improve the understanding and management of complex mental health disorders. Full article
(This article belongs to the Special Issue What Is New in Psychiatry and Psychopharmacology—2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

27 pages, 1019 KiB  
Review
Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism
by Federico Mucci, Alessandro Arone, Riccardo Gurrieri, Francesco Weiss, Gerardo Russomanno and Donatella Marazziti
Life 2025, 15(3), 391; https://doi.org/10.3390/life15030391 - 1 Mar 2025
Viewed by 1365
Abstract
Antipsychotic drugs (APs) have profoundly changed the treatment landscape for psychiatric disorders, yet their impact on neuroplasticity and neurotrophism remains only partially understood. While second-generation antipsychotics (SGAs) are associated with a better side effect profile than their predecessors, the emergence of third-generation antipsychotics [...] Read more.
Antipsychotic drugs (APs) have profoundly changed the treatment landscape for psychiatric disorders, yet their impact on neuroplasticity and neurotrophism remains only partially understood. While second-generation antipsychotics (SGAs) are associated with a better side effect profile than their predecessors, the emergence of third-generation antipsychotics (TGAs)—such as brexpiprazole, cariprazine, lurasidone, iloperidone, lumateperone, pimavanserin, and roluperidone—has prompted renewed interest in their potential neuroprotective and pro-cognitive effects. This review attempts to carefully examine the evidence on the neurotrophic properties of TGAs and their role in modulating brain plasticity by analyzing studies published between 2010 and 2024. Although data remain limited and focused primarily on earlier SGAs, emerging findings suggest that some TGAs may exert positive effects on neuroplastic processes, including the modulation of brain-derived neurotrophic factors (BDNFs) and synaptic architecture. However, robust clinical data on their long-term effects and comparative efficacy are lacking; therefore, further research is necessary to validate their role in preventing neurodegenerative changes and improving cognitive outcomes in patients with psychiatric conditions. Full article
(This article belongs to the Special Issue What Is New in Psychiatry and Psychopharmacology—2nd Edition)
►▼ Show Figures

Figure 1

26 pages, 5486 KiB  
Review
The Potential Role of Polyphenol Supplementation in Preventing and Managing Depression: A Review of Current Research
by Mohd Farhan and Mohd Faisal
Life 2024, 14(10), 1342; https://doi.org/10.3390/life14101342 - 21 Oct 2024
Cited by 1 | Viewed by 2489
Abstract
Depression is a common mental illness that affects 5% of the adult population globally. The most common symptoms of depression are low mood, lack of pleasure from different activities, poor concentration, and reduced energy levels for an extended period, and it affects the [...] Read more.
Depression is a common mental illness that affects 5% of the adult population globally. The most common symptoms of depression are low mood, lack of pleasure from different activities, poor concentration, and reduced energy levels for an extended period, and it affects the emotions, behaviors, and overall well-being of an individual. The complex pathophysiology of depression presents challenges for current therapeutic options involving a biopsychosocial treatment plan. These treatments may have a delayed onset, low remission and response rates, and undesirable side effects. Researchers in nutrition and food science are increasingly addressing depression, which is a significant public health concern due to the association of depression with the increased incidence of cardiovascular diseases and premature mortality. Polyphenols present in our diet may significantly impact the prevention and treatment of depression. The primary mechanisms include reducing inflammation and oxidative stress, regulating monoamine neurotransmitter levels, and modulating the microbiota–gut–brain axis and hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis. This review summarizes recent advances in understanding the effects of dietary polyphenols on depression and explores the underlying mechanisms of these effects for the benefit of human health. It also highlights studies that are looking at clinical trials to help future researchers incorporate these substances into functional diets, nutritional supplements, or adjunctive therapy to prevent and treat depression. Full article
(This article belongs to the Special Issue What Is New in Psychiatry and Psychopharmacology—2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop